The Community Guide

- gsearch

Search Results

Narrow Results:

2013 1
2012 1
2011 1

Journal Article 3

1 - 3 of 3 Results

Refine Results

Refine Results:

Fasting Glucose Level Modulates Cell Surface Expression of CD11b and CD66b in Granulocytes and Monocytes of Patients with Type II Diabetes

CITE Title : Fasting Glucose Level Modulates Cell Surface Expression of CD11b and CD66b in Granulocytes and Monocytes of Patients with Type II Diabetes Personal Author(s) : Horvath, Peter;Oliver, Stacy R.;Ganesan, Goutham;Zaldivar, Frank P.;Radom-Aizik, Shlomit;Galassetti, Pietro R.; Published Date : Aug 2013 Source : J Investig Med. 61(6):972-977 URL : https://stacks.cdc.gov/view/cdc/29703 Horvath, Peter et al. (2013). Fasting Glucose Level Modulates Cell Surface Expression of CD11b and CD66b in Granulocytes and Monocytes of Patients with Type II Diabetes. 61(6). Horvath, Peter et al. "Fasting Glucose Level Modulates Cell Surface Expression of CD11b and CD66b in Granulocytes and Monocytes of Patients with Type II Diabetes" 61, no. 6 (2013) Horvath, Peter et al. "Fasting Glucose Level Modulates Cell Surface Expression of CD11b and CD66b in Granulocytes and Monocytes of Patients with Type II Diabetes" vol. 61, no. 6, 2013 Export RIS Citation Information.

:

Horvath, Peter ;

Oliver, Stacy R.

Aug 2013 | J Investig Med. 61(6):972-977

:

Cardiovascular complications are the leading cause of mortality in type 2 diabetes (T2DM), in which onset and progression of atherosclerosis is linked...
Tissue and serum mesothelin are potential markers of neoplastic progression in Barrett’s–associated esophageal adenocarcinoma

CITE Title : Tissue and serum mesothelin are potential markers of neoplastic progression in Barrett’s–associated esophageal adenocarcinoma Personal Author(s) : Rizk, Nabil P.;Servais, Elliot L.;Tang, Laura H.;Sima, Camelia S.;Gerdes, Hans;Fleisher, Martin;Rusch, Valerie W.;Adusumilli, Prasad S.; Published Date : 3 2012;3-2012; Source : Cancer Epidemiol Biomarkers Prev. 21(3):482-486 URL : https://stacks.cdc.gov/view/cdc/33317 Rizk, Nabil P. et al. (2012). Tissue and serum mesothelin are potential markers of neoplastic progression in Barrett’s–associated esophageal adenocarcinoma. 21(3). Rizk, Nabil P. et al. "Tissue and serum mesothelin are potential markers of neoplastic progression in Barrett’s–associated esophageal adenocarcinoma" 21, no. 3 (2012) Rizk, Nabil P. et al. "Tissue and serum mesothelin are potential markers of neoplastic progression in Barrett’s–associated esophageal adenocarcinoma" vol. 21, no. 3, 2012 Export RIS Citation Information.

:

Rizk, Nabil P. ;

Servais, Elliot L.

3 2012 | Cancer Epidemiol Biomarkers Prev. 21(3):482-486

:

BackgroundMesothelin is overexpressed in several malignancies and is purportedly a specific marker of malignant transformation. In this pilot study, w...
An In Vivo Platform for Tumor Biomarker Assessment

CITE Title : An In Vivo Platform for Tumor Biomarker Assessment Personal Author(s) : Servais, Elliot L.;Suzuki, Kei;Colovos, Christos;Rodriguez, Luis;Sima, Camelia;Fleisher, Martin;Rusch, Valerie W.;Sadelain, Michel;Adusumilli, Prasad S.; Published Date : Oct 26 2011 Source : PLoS One. 2011; 6(10). URL : https://stacks.cdc.gov/view/cdc/22796 Servais, Elliot L. et al. (2011). An In Vivo Platform for Tumor Biomarker Assessment. 6(10). Servais, Elliot L. et al. "An In Vivo Platform for Tumor Biomarker Assessment" 6, no. 10 (2011) Servais, Elliot L. et al. "An In Vivo Platform for Tumor Biomarker Assessment" vol. 6, no. 10, 2011 Export RIS Citation Information.

:

Servais, Elliot L. ;

Suzuki, Kei

Oct 26 2011 | PLoS One. 2011; 6(10).

:

Tumor biomarkers provide a quantitative tool for following tumor progression and response to therapy. However, investigations of clinically useful tum...